Table 10.

Sensitivity analysis in the estimation of the SLE risk for Hashimoto’s thyroiditis exposure in the age-matched and sex-matched population. Follow-up duration of samples ≧ 6 months

		Model 3, aHRa (95%CI)
Scenario 1	Definition of SLE event: major illness registry (main finding)	4.13 (3.02–5.65)
Scenario 2	Definition of SLE event: scenario 1 + treated with systemic corticosteroids or DMARDs (including HCQ or azathioprine)	4.23 (3.09–5.79)
Scenario 3	Definition of SLE event: scenario 1 + treated with DMARDs (including HCQ or azathioprine)b	5.18 (3.70–7.26)
Scenario 4	Exclusion of patients with RA, SS, SSc, vasculitis, AS, and IBD at baseline (excluding autoimmune thyroiditis accompanied with other autoimmune diseases)	4.70 (3.39–6.51)

aHR Adjusted HR, HCQ Hydroxychloroquine, RA Rheumatoid arthritis, SS Sjögren’s syndrome, SSc Systemic sclerosis, AS Ankylosing spondylitis, IBD Inflammatory bowel disease, SLE Systemic lupus erythematosus

^aaHR: the covariates including urbanization, low income, and comorbidities listed in Table 1

^bThe treatment of SLE was identified within 6 months after the first diagnosis of SLE